VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement on Tues
TORONTO--(BUSINESS WIRE)--$HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today t
TORONTO--(BUSINESS WIRE)--Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) ("Kontrol” or "Company") a leader in smart buildings and cities through IoT, Cloud and SaaS technology will report will its financial results for the three month peri
Oral presentation of clinical data from the Phase 1/2 TRESR Trial of camonsertib (also known as RP-3500) monotherapy in solid tumors at 2022 AACR Annual Meeting Results demonstrated robust activity in ovarian cancer with a 75% CBR, 25% ORR and 35 weeks
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that an abstract highlighting preclinical data for its de
Study results were included in the submission to Health Canada leading to Notice of Compliance QUEBEC CITY--(BUSINESS WIRE)--Medicago today announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine (plant-based virus
PARIS--(BUSINESS WIRE)--Egle Therapeutics SAS (Egle), an emerging biotechnology company dedicated to developing novel immunotherapies for oncology and autoimmune diseases, is pleased to announce Pierre Legault as Chairman and board member as of March 2022
WINNIPEG, Manitoba--(BUSINESS WIRE)--Farmers Edge Inc. (“Farmers Edge” or the “Company”) (TSX: FDGE) announced today that the Company’s 2022 first quarter financial results will be released after market close on Thursday, May 12, 2022. At that t
Last patient enrolled ahead of expectations in pivotal trial evaluating zanidatamab as monotherapy in 2L biliary tract cancers (BTC) Two zanidatamab data presentations at ASCO in June: 1L breast cancer and 1L gastroesophageal adenocarcinoma (GEA)
Live Call/Audio Webcast to Begin at 5:00 pm ET Today TORONTO & DALLAS--(BUSINESS WIRE)--Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer s
Our partner BioTalent Canada has launched the Building Workplace Resiliency resources for its I.D.E.A.L. Biosciences Employer Recognition Program. This program served as a guide for employers seeking to submit fall program applications.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.